VolitionRx Limited (VNRX)
0.66
0.04 (6.28%)
At close: Jan 14, 2025, 3:59 PM
0.66
0.02%
After-hours Jan 14, 2025, 08:00 PM EST
undefined% (undefined)
| Bid | 0.62 |
| Market Cap | 63.33M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.36 |
| PE Ratio (ttm) | -1.83 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 0.68 |
| Volume | 49,686 |
| Avg. Volume (20D) | 275,521 |
| Open | 0.60 |
| Previous Close | 0.62 |
| Day's Range | 0.60 - 0.66 |
| 52-Week Range | 0.43 - 1.23 |
| Beta | undefined |
About VNRX
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company ope...
Industry Medical - Diagnostics & Research
Sector Healthcare
IPO Date Mar 2, 2012
Employees 101
Stock Exchange AMEX
Ticker Symbol VNRX
Website https://www.volition.com
Analyst Forecast
According to 4 analyst ratings, the average rating for VNRX stock is "Buy." The 12-month stock price forecast is $5, which is an increase of 657.69% from the latest price.
Buy 50.00%
Hold 25.00%
Sell 0.00%
5 months ago ·
Source
-7.19%
VolitionRx shares are trading lower after the comp...
Unlock content with
Pro Subscription
8 months ago ·
Source
-14.53%
VolitionRx shares are trading lower after the company reported worse-than-expected Q1 sales results.
